Communiqués Axogen, Inc.

Actions

AXGN

US05463X1063

Equipement et technologie médicale avancés

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 20/07/2026			Varia. 5j.	Varia. 1 janv.
39,48 ^USD	-0,93%		-0,03%	+20,62%

22:56	Neuronetics nomme Nir Naor au poste de directeur financier	MT
13/07	Bosch lance la production d'échantillons dans sa première usine de semi-conducteurs aux États-Unis	RE

Communiqués

15/07	Axogen, Inc. to Report Second Quarter 2026 Financial Results on July 29, 2026	GL
22/05	The Newest Name on Nasdaq Wants to Help the Body Rebuild Itself	AQ
30/04	Axogen, Inc. to Participate in the 2026 Bank of America Global Healthcare Conference	GL
28/04	Axogen : Q1 2026 Financial Results Presentation	PU
28/04	AxoGen: Q1 Earnings Snapshot	AQ
28/04	Axogen, Inc. Reports First Quarter 2026 Financial Results	GL
14/04	Axogen, Inc. to Report First Quarter 2026 Financial Results on April 28, 2026	GL
14/04	Axogen, Inc. to Report First Quarter 2026 Financial Results on April 28, 2026	AQ
25/02	Axogen : Conference Call Presentation FY 2025	PU
24/02	Axogen : Q4 2025 Financial Results Presentation	PU
24/02	AxoGen: Q4 Earnings Snapshot	AQ
24/02	Axogen, Inc. Reports Fourth Quarter and Full-Year 2025 Financial Results	GL
17/02	Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences	GL
10/02	Axogen, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026	GL
22/01	Axogen Announces Pricing of Upsized $124 Million Public Offering of Common Stock	GL
21/01	Axogen Announces Proposed Public Offering of Common Stock	GL
15/01	Axogen : J.P. Morgan 2026 Healthcare Conference	PU
12/01	Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025	GL
12/01	Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025	AQ
17/12	Axogen, Inc. to Participate in the J.P. Morgan 2026 Healthcare Conference	GL
17/12	Axogen, Inc. to Participate in the J.P. Morgan 2026 Healthcare Conference	AQ
04/12	Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)	GL
04/11	Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences	GL
29/10/25	AxoGen: Q3 Earnings Snapshot	AQ
29/10/25	Axogen : Q3 2025 Financial Results Presentation	PU